Sugi Predict

Sugi Predict / Compounds / SCHEMBL569285

SCHEMBL569285

SCHEMBL569285

CCn1ncc(N)c1C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ TSHR P16473 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.40
▸ MAPT P10636 2/20 0.40
▸ BLM P54132 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GLA P06280 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ DAPK3 O43293 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ PRKD3 O94806 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7516717 0.85 LMNA (0.47) KDM4EKMT2ATSHRHSD17B10MEN1
SCHEMBL12725196 0.84 ALDH1A1 (0.37) KDM4ETSHRHSD17B10GAAALDH1A1
SCHEMBL28805092 0.83 ALDH1A1 (0.39) KDM4ETSHRHSD17B10GAAALDH1A1
SCHEMBL18256045 0.81 CFTR (0.36) KDM4ETSHRHSD17B10GAAALDH1A1
SCHEMBL19892917 0.81 ALDH1A1 (0.36) KDM4EKMT2ATSHRHSD17B10GAA
SCHEMBL7992220 0.81 ALDH1A1 (0.43) KDM4EKMT2ATSHRHSD17B10GAA
SCHEMBL18256078 0.80 LMNA (0.47) KDM4EGAAALDH1A1GLAMAPK1
SCHEMBL31332838 0.80 KMT2A (0.58) KDM4EKMT2ATSHRHSD17B10GAA
SCHEMBL7515582 0.80 POLB (0.46) KDM4EKMT2ATSHRHSD17B10GAA
SCHEMBL23408461 0.79 SMN1; SMN2 (0.56) KMT2ATSHRMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617799-B2 Pyrazolopyrimidinone compounds Orphagen Pharmaceuticals, Inc. (US) 2026-05-05 — — US disclosed
US-20240208982-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. 2024-06-27 — — US disclosed
EP-4313988-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2024-02-07 — — EP disclosed
CN-117396480-A Pyrazolopyrimidinone compounds 奥弗恩制药公司 2024-01-12 — — CN disclosed
US-20230018728-A1 PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2023-01-19 — — US disclosed
WO-2022204481-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2022-09-29 — — WO disclosed
WO-2022204481-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2022-09-29 — — WO disclosed
EP-3287441-B1 ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE TAKEDA PHARMACEUTICALS CO (JP) 2021-06-09 — — EP disclosed
WO-2021098811-A1 PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2021-05-27 — — WO disclosed
CN-107848971-B Heterocyclic compounds 武田药品工业株式会社 2021-03-26 — — CN disclosed
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 — — EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 — — US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 — — US disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 — — EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 — — WO disclosed
US-7932257-B2 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2011-04-26 — — US disclosed
US-7932257-B2 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2011-04-26 — — US disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 — — US disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 — — US disclosed
WO-2007013964-A1 PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2007-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230018728-A1 PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF WEE1, WEE2, ATR KDM4E 2250/4885KMT2A 1459/4885TSHR 3390/4885
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A KDM4E 1619/4885KMT2A 780/4885TSHR 395/4885
US-20240208982-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS CYP2C19, CYP3A4, CYP2C9 KDM4E 3506/4885KMT2A 4447/4885TSHR 3807/4885
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors AURKA, AURKB, AURKC KDM4E 951/4885KMT2A 622/4885TSHR 3322/4885
US-12617799-B2 Pyrazolopyrimidinone compounds CYP2B6, CBR1, CYP2D6 KDM4E 3845/4885KMT2A 4415/4885TSHR 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.